Delos Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Delos Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	445
2021 Q3	$0	Buy	+1	New	+$5	﹤0.01%	218

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Delos Wealth Advisors's CPRX Position: Q4 2021 in Review

Delos Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2021, closing a stake of 1 share.

Delos Wealth Advisors first reported a position in CPRX in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 164 funds tracked by Wall St. Rank hold CPRX as of Q4 2021.

Delos Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2021 after selling out during the quarter.
Delos Wealth Advisors sold 1 Catalyst Pharmaceutical share in Q4 2021.
Delos Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q3 2021 and held it in 1 quarter.
Delos Wealth Advisors's Catalyst Pharmaceutical position peaked at $0 in Q3 2021.
164 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2021.

Based on Delos Wealth Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.